Amitriptyline is an efficacious antidepressant drug .
It is , however , also associated with a number of side effects .
Degree of placebo response and severity of depression at baseline may moderate drug-placebo efficacy differences
BACKGROUND Amitriptyline is a tricyclic antidepressant that was synthesis ed in 1960 and introduced as early as 1961 in the USA , but is still regularly used .
It has also been frequently used as an active comparator in trials on newer antidepressants and can therefore be called a ' benchmark ' antidepressant .
However , its efficacy and safety compared to placebo in the treatment of major depression has not been assessed in a systematic review and meta- analysis .
OBJECTIVES To assess the effects of amitriptyline compared to placebo or no treatment for major depressive disorder in adults .
Treating the depressed elderly patient: the comparative behavioral pharmacology of mianserin and amitriptyline.
MIA is an effective antidepressant , comparable in therapeutic efficacy to the TCAs . Further , because of its weak antimuscarinic effects . Further , because of its weak antimuscarinic effects , MIA produces no significant cognitive impairment , alteration of cardiovascular function of anticholinergic side effects compared to the TCA 's . While drowsiness is the most frequently reported adverse reaction with MIA , an h.s . dosing schedule can provide relief of insomnia and improve the quality of sleep ( 47,61 ) . Therefore , because of MIA 's advantageous pharmacodynamic profile , it offers an improvement in therapeutic index over the TCAs in the treatment of depression in the elderly
Amitriptyline is an efficacious antidepressant drug .
It is , however , also associated with a number of side effects .
Degree of placebo response and severity of depression at baseline may moderate drug-placebo efficacy differences
BACKGROUND Amitriptyline is a tricyclic antidepressant that was synthesis ed in 1960 and introduced as early as 1961 in the USA , but is still regularly used .
It has also been frequently used as an active comparator in trials on newer antidepressants and can therefore be called a ' benchmark ' antidepressant .
However , its efficacy and safety compared to placebo in the treatment of major depression has not been assessed in a systematic review and meta- analysis .
OBJECTIVES To assess the effects of amitriptyline compared to placebo or no treatment for major depressive disorder in adults .